Collectedly, our data suggest silencing circPDHK1 can partially enhance the anti-tumor efficacy and sensitivity of TKI drugs or AKT-mTOR inhibitors for ccRCC in vitro. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.